NEW YORK, March 1 (GenomeWeb News) - Alnylam Pharmaceuticals has filed a statement with the SEC for an initial public offering, the company said Friday evening.
The number of shares of common stock Alnylam plans to offer, and their price, have yet to be determined. Bank of America Securities serves as the company's book-runner and lead manager.
Alnylam, based in Cambridge, Mass., plans to develop drugs based on RNA interference.
Alnylam would be one of the first companies in the genomics sector in several years to go public: Two years ago, ZymoGenetics raised $120 million in its initial public offering.